Press releases
- Innate Pharma Reports Full Year 2023 Financial Results and Business Update
- Innate Pharma Announces Its Participation to Upcoming Investor Conference
- Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
- Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
- Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
- Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
- Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
- Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
More ▼
Key statistics
As of last trade, Innate Pharma SA (IDDA:FRA) traded at 2.14, 14.44% above the 52 week low of 1.87 set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.00 |
---|---|
High | 2.14 |
Low | 2.00 |
Bid | 2.16 |
Offer | 2.24 |
Previous close | 2.16 |
Average volume | 0.00 |
---|---|
Shares outstanding | 80.86m |
Free float | 62.11m |
P/E (TTM) | -- |
Market cap | 191.78m USD |
EPS (TTM) | -0.0912 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 08:59 BST.
More ▼